- €264.38m
- €290.94m
- €62.58m
Brief: Lavipharm FY Net Profit At EUR 0.8 Million, Down 51.9% YoY
Brief: Lavipharm To Refinance Debt Though Issuance Of 7-year Syndicated Bond Loan Of Up To EUR 15.0 Million
Brief: Lavipharm Q3 EBITDA Down To EUR 1.5 Million
Brief: Lavipharm H1 Net Profit Down To EUR 1.9 Million
Brief: Lavipharm's EGM Approves Share Capital Increase Of Up To EUR 58.0 Million
Brief: Lavipharm AGM Has Approved A 3-For-1 Reverse Share Split
Brief: Lavipharm FY 2021 Net Profit Drops To EUR 1.7 Million
Brief: Lavipharm Q3 EBITDA Up At EUR 1.7 Million
Brief: Lavipharm To Appoint Vassilis Baloumis As Chief Financial Officer
Brief: Lavipharm H1 Net Profit Up At EUR 2.6 Million
Brief: Lavipharm Sees Non-Renewal Of Contract With PTC Therapeutics Decreasing FY 2022 Turnover By C. EUR 1.0 Million
Brief: Lavipharm Says Contract With PTC Therapeutics Is Not Going To Be Renewed
Brief: Lavipharm BOD Appoints New Chairman and New Executive Member
Brief: Lavipharm Announces Athanasios Lavidas President Of The Company Passed Away
Brief: Lavipharm FY Net Profit Down At EUR 2.2 Million YoY
Brief: Lavipharm Q3 Sales Raises To EUR 9.13 Million
Brief: Lavipharm H1 Net Profit Up At EUR 2.2 Million YoY
Brief: Lavipharm Signs 5-Year Exclusive Cooperation Agreement With Zentiva
Brief: Lavipharm FY Net Profit Up At EUR 5.3 Million YoY